Teva Pharmaeutical Stock Gets Upgrade From Analyst | Barron's
Is the new Teva x Ugg collection fashion-forward or just plain ugly? - MarketWatch
Teva shares drop 3% after rival generic product approved and launched - MarketWatch
Teva's Battered Stock Looks Extremely Cheap | Barron's
Teva stock drops on guidance, manufacturing problems - MarketWatch
Teva Stock Is Falling as an Analyst Says It Needs 'Numerous Litigation Wins' | Barron's
Teva Pharmaceutical TEVA Investment Analysis - MarketWatch
Teva Pharmaceutical Names Richard Francis as CEO, President - WSJ
Teva's generic EpiPen approved in the U.S., with perfect timing - MarketWatch
TEVA | Teva Pharmaceutical Industries Ltd. ADR Stock Overview (U.S.: NYSE) | Barron's
Teva to acquire Mexico's Rimsa for $2.3 billion - MarketWatch
Teva beats first-quarter expectations but still has the same old problems - MarketWatch
Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Announces Abstracts at the ACAAI Annual Scientific Meeting
TEVA | Teva Pharmaceutical Industries Ltd. ADR Stock Overview (U.S.: NYSE) | Barron's
Israel stocks rise, led by Teva, ICL - MarketWatch
Teva Pharmaceuticals reports earnings on Wednesday. Here's what to expect - MarketWatch
Teva's Earnings and Outlook Miss Estimates. Currency Moves Are to Blame. | Barron's
Drug Stock Due for Another Climb on the Charts
Teva Pharmaceuticals (@TevaUSA) / Twitter
Teva Tries to Put an End to the Opioid Wars - WSJ
Teva Stock Climbs as Earnings Hint at Turnaround | Barron's
Teva Stock Jumps Following Tentative Deal to Settle Opioid Cases | Barron's
TEVA -- Is Its Stock Price A Worthy Investment? Learn More.
Investors wary of Teva-Mylan merger - MarketWatch
Mylan sees opportunity in rival Teva's weakness - MarketWatch
Teva Pharmaceutical's Stock Tumbles on Outlook - WSJ
